Patents Represented by Attorney, Agent or Law Firm Robert D. Titus
  • Optical resolution of aminoisobobutyric acid
    Patent number: 6372936
    Abstract: A process for resolving amino protected racemic 3-amino-2-methylpropionic acid which comprises the steps of: (1) reacting said amino protected acid with a protected amino group with an enantiomer of a chiral amine to form diastereomeric salts; (2) recrystallizing the diastereomeric salts from ethyl acetate to separate the diastereomeric salts into crystal fractions; and (3) releasing the resolved acid from the diastereomeric salt by treating the diastereomeric salt with a basic solution is disclosed. A process for the preparation of the cryptophycin molecules is also disclosed.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: April 16, 2002
    Assignee: Eli Lilly and Company
    Inventors: James Abraham Aikins, Tony Yantao Zhang
  • 5-HT1F agonists
    Patent number: 6358972
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1f receptors and inhibiting protein extravasation in a mammal.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: March 19, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Daniel James Koch, Brian Michael Mathes, Vincent Patrick Rocco
  • Inhibitors of serotonin reuptake
    Patent number: 6303627
    Abstract: This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: October 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Daniel James Koch, Vincent Patrick Rocco
  • Pharmaceutical packaging system
    Patent number: 6273260
    Abstract: A packaging system for storing and dispensing individual doses of medication on prescribed days, the packaging system comprising a series of sheets adapted to fold over each other with doses of medication removably held thereon. A plurality of labels are held on at least one of the sheets, each label corresponding to one dose of medication, each of the labels being adapted to be removed from one of the sheets and applied to a calendar to thereby serve as a reminder of the day on which the corresponding individual dose of medication is to be taken. The packaging system may further comprise a sleeve with one open end, the open end and the sleeve engaging the sheets when in a folded state.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: August 14, 2001
    Assignee: Eli Lilly and Company
    Inventors: Ralph ColDepietro, Daniel F. Lynch
  • 5-HT1F antagonists
    Patent number: 6242450
    Abstract: This invention provides 5-HT1f antagonists of Formula I: where AR1, AR2, R, and R′ are as defined in the specification.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: June 5, 2001
    Assignee: Eli Lilly and Company
    Inventors: Daniel James Koch, Lee Alan Phebus, Vincent Patrick Rocco, Tammy Joy Sajdyk
  • Carboxamides useful as 5-HT1F agonists
    Patent number: 6221884
    Abstract: The present invention provides novel 2-amino-1,2,3,4-tetrahydro-9H-carbazole-6-carboxamides and 3-amino-10H-cyclohepta[7,6-b]indole-7-carboxamides of Formula I: where R1, R2, R3 and n are as described in the specification.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: April 24, 2001
    Assignee: Eli Lilly and Company
    Inventor: Michael Edward Flaugh
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6204260
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: March 20, 2001
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin DG Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Treatment of conduct disorder
    Patent number: 6184222
    Abstract: Norepinephrine reuptake inhibitors are used to treat conduct disorder.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: February 6, 2001
    Assignee: Eli Lilly and Company
    Inventor: John Harrison Heiligenstein
  • Melatonin derivatives for use in treating desynchronization disorders
    Patent number: 6180657
    Abstract: The present invention provides a method of treating desynchronization disorders using various melatonin analogs.
    Type: Grant
    Filed: November 18, 1993
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventor: Michael E. Flaugh
  • Potentiation of drug response
    Patent number: 6169105
    Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: January 2, 2001
    Assignee: Eli Lilly and Company
    Inventors: David Taiwai Wong, Juan Ignacio Oguiza
  • Pyrrolo [3,2-b]pyridine processes and intermediates
    Patent number: 6150525
    Abstract: The present invention provides processes and intermediates of Formula I: ##STR1## where X and R are defined in the specification, for the preparation of 5-amino-3-(1-methylpiperidin-4-yl)pyrrolo-[3,2-b]pyridine.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: November 21, 2000
    Assignee: Eli Lilly and Company
    Inventors: Vincent Mancuso, Freddy Andre Napora, Uko Effiong Udodong, Daniel Edward Verral, II
  • Combination therapy for treatment of psychoses
    Patent number: 6147072
    Abstract: The invention relates to a method of treating psychosis, acute mania, mild anxiety states or depression in combination with psychotic episodes by administering to a patient a combination of an atypical antipsychotic and a serotonin reuptake inhibitor.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: November 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Franklin P. Bymaster, Kenneth W. Perry, Gary D. Tollefson
  • Antitumor compositions and methods of treatment
    Patent number: 6147115
    Abstract: This invention provides certain sulfonamide compounds, formulations, and a method for treating susceptible neoplasms in mammals using certain sulfonamide compounds.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, J. Jeffry Howbert, John S. Ward
  • 5-HT.sub.1F agonists
    Patent number: 6133290
    Abstract: The present invention relates to a compound of formula I: ##STR1## or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT.sub.1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Joseph Herman Krushinski, Jr., John Mehnert Schaus
  • Polymer bound carbodiimide coupling reagent
    Patent number: 6126932
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula ##STR1## where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: October 3, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
  • Inhibition of serotonin reuptake
    Patent number: 6107307
    Abstract: This invention provides 3-(bicyclic heteroaryl)-8-azabicyclo[3.2.1]oct-2-enes and 3-(bicyclic heteroaryl)-8-azabicyclo[3.2.1]octanes which are useful for the inhibition of serotonin reuptake in mammals.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: August 22, 2000
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Stacey Leigh McDaniel, Jeffrey Scott Nissen
  • Inhibition of serotonin reuptake
    Patent number: 6046215
    Abstract: This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: April 4, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Daniel J. Koch, Thomas E. Mabry, Jeffrey S. Nissen, Vincent P. Rocco, Yao-Chang Xu
  • Treatment of attention-deficit/hyperactivity disorder
    Patent number: 6046193
    Abstract: Reboxetine is used to treat attention-deficit/hyperactivity disorder.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: April 4, 2000
    Assignee: Eli Lilly and Company
    Inventor: John Harrison Heiligenstein
  • Treatment of oppositional defiant disorder
    Patent number: 6028070
    Abstract: Norepinephrine reuptake inhibitors are used to treat oppositional defiant disorder.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: February 22, 2000
    Assignee: Eli Lilly and Company
    Inventor: John Harrison Heiligenstein
  • Preparation of 4-halo and 6-halomelatonins
    Patent number: 6022980
    Abstract: This invention provides an improved process for the preparation and separation of 4-halo and 6-halomelatonins.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: February 8, 2000
    Assignee: Eli Lilly and Company
    Inventor: Michael Edward Flaugh